Librería: ThriftBooks-Dallas, Dallas, TX, Estados Unidos de America
EUR 14,27
Cantidad disponible: 1 disponibles
Añadir al carritoHardcover. Condición: Good. No Jacket. Pages can have notes/highlighting. Spine may show signs of wear. ~ ThriftBooks: Read More, Spend Less.
EUR 167,40
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
Librería: Ria Christie Collections, Uxbridge, Reino Unido
EUR 153,57
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. In.
EUR 153,56
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
EUR 172,40
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: California Books, Miami, FL, Estados Unidos de America
EUR 187,24
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
EUR 171,19
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Idioma: Inglés
Publicado por Wiley-VCH Verlag GmbH, DE, 2015
ISBN 10: 3527335110 ISBN 13: 9783527335114
Librería: Rarewaves.com USA, London, LONDO, Reino Unido
EUR 201,60
Cantidad disponible: Más de 20 disponibles
Añadir al carritoHardback. Condición: New. With its focus on emerging concerns of kinase and GPCR-mediated antitarget effects, this vital reference for drug developers addresses one of the hot topics in drug safety now and in future. Divided into three major parts, the first section deals with novel technologies and includes the utility of adverse event reports to drug discovery, the translational aspects of preclinical safety findings, broader computational prediction of drug side-effects, and a description of the serotonergic system. The main part of the book looks at some of the most common antitarget-mediated side effects, focusing on hepatotoxicity in drug safety, cardiovascular toxicity and signaling effects via kinase and GPCR anti-targets. In the final section, several case studies of recently developed drugs illustrate how to prevent anti-target effects and how big pharma deals with them if they occur. The more recent field of systems pharmacology has gained prominence and this is reflected in chapters dedicated to the utility in deciphering and modeling anti-targets. The final chapter is concerned with those compounds that inadvertently elicit CNS mediated adverse events, including a pragmatic description of ways to mitigate these types of safety risks. Written as a companion to the successful book on antitargets by Vaz and Klabunde, this new volume focuses on recent progress and new classes, methods and case studies that were not previously covered.
EUR 169,00
Cantidad disponible: 5 disponibles
Añadir al carritoGebunden. Condición: New. Laszlo Urban received his MD and PhD in neurophysiology/neuropharmacology in Hungary, and was visiting professor at Duke University between 1987 and 1989. He is currently global head of Preclinical Safety Profiling at the Novartis Institutes for Biomedical .
Idioma: Inglés
Publicado por Wiley-VCH Verlag GmbH, DE, 2015
ISBN 10: 3527335110 ISBN 13: 9783527335114
Librería: Rarewaves.com UK, London, Reino Unido
EUR 190,63
Cantidad disponible: Más de 20 disponibles
Añadir al carritoHardback. Condición: New. With its focus on emerging concerns of kinase and GPCR-mediated antitarget effects, this vital reference for drug developers addresses one of the hot topics in drug safety now and in future. Divided into three major parts, the first section deals with novel technologies and includes the utility of adverse event reports to drug discovery, the translational aspects of preclinical safety findings, broader computational prediction of drug side-effects, and a description of the serotonergic system. The main part of the book looks at some of the most common antitarget-mediated side effects, focusing on hepatotoxicity in drug safety, cardiovascular toxicity and signaling effects via kinase and GPCR anti-targets. In the final section, several case studies of recently developed drugs illustrate how to prevent anti-target effects and how big pharma deals with them if they occur. The more recent field of systems pharmacology has gained prominence and this is reflected in chapters dedicated to the utility in deciphering and modeling anti-targets. The final chapter is concerned with those compounds that inadvertently elicit CNS mediated adverse events, including a pragmatic description of ways to mitigate these types of safety risks. Written as a companion to the successful book on antitargets by Vaz and Klabunde, this new volume focuses on recent progress and new classes, methods and case studies that were not previously covered.
Librería: PBShop.store UK, Fairford, GLOS, Reino Unido
EUR 157,00
Cantidad disponible: Más de 20 disponibles
Añadir al carritoHRD. Condición: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.